Trials / Terminated
TerminatedNCT02399839
Global Lomitapide Pregnancy Exposure Registry
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 5 (actual)
- Sponsor
- Amryt Pharma · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the outcomes of pregnancy in women treated with lomitapide.
Detailed description
To evaluate the outcomes of pregnancy in women treated with lomitapide at any time within 30 days prior to first day of Last Menstrual Period (LMP) or during pregnancy. The outcomes of primary interest are major congenital anomalies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lomitapide | As prescribed by Physician. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2015-03-26
- Last updated
- 2022-12-16
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02399839. Inclusion in this directory is not an endorsement.